



Pfizer ApS
Lautrupvang 8
DK-2750 Ballerup
Tlf.: 44 20 11 00
Fax: 44 20 11 01
www.pfizer.dk

DK66351912

Danmarks Bløderforening
Blekinge Boulevard 2, Høje Taastrup, Taastrup, 2630 Hovedstaden, Denmark
Att.: Karen Binger Holm

Ballerup, March 04, 2026

Agreement on support to:

Pfizer wishes to provide support to Danmarks Bløderforening - DBF and has therefore entered into this Agreement with Danmarks Bløderforening (hereafter referred to as the Recipient).

The purpose of this agreement shall be support DBF to organize the annual meeting.

The agreement shall be in effect from April 18, 2026 to April 19, 2026.

Pfizer's financial commitment in relation to this Agreement shall be DKK 43.342,00 excl. VAT.

Pfizer will not provide any non-financial support.

Roles of the parties in the project

Pfizer undertakes to provide support as per this Agreement.

The Recipient undertakes to conduct the activity in a professional manner and in compliance with the Promotion Code of the Ethical Committee for the Pharmaceutical Industry (ENLI).

The support Pfizer will provide is given under the condition that it is used to cover expenses in connection with academic and scientific activities including appropriate amount of food and beverages.

It may not be used to sponsor or organize activities of a solely social or cultural character or any other non-academic activities.

Any promotional activity/display must be separated from all academic and scientific activities and in addition it must be separated from the general public.

Please be aware that according to ENLI rules no gifts must be provided to healthcare professionals, unless they fall into a category of items that are otherwise permitted under the ENLI Promotion Code. This prohibition applies for all activities sponsored or co-sponsored by a pharmaceutical company.

If the support provided by Pfizer is fully or partly spent on an activity performed by a healthcare professional that is subject to the law regarding healthcare professionals' affiliation with pharmaceutical companies, then you must ensure that:

- The healthcare professional is informed to report affiliation with Pfizer to the Danish Medicines Agency, and
- Pfizer is informed of the healthcare professional's full name, email address, workplace, authorization ID, time period of the activity (date(s)) and the amount of payment received by the healthcare professional.

Note:

If the activity does NOT fall under the following categories: Teaching/lecturing, Professional information without advertising purposes, and Research, then the healthcare professional must request and await permission from the Danish Medicines Agency before commencing the activity.

Report of activity to ENLI

The sponsorship is reported to ENLI, prior to the activity and by Pfizer's opinion it is in compliance with all applicable rules although the arrangement has not been pre-approved by ENLI.

Documentation

Upon Pfizer's request, the Recipient shall provide documentation that the support is spent in accordance with the Agreement and that the combined support does not exceed the actual expenses. Any surplus shall be refunded to Pfizer.

Data Privacy

By signing this Agreement the Recipient agrees that Pfizer archives information about the Recipient and persons employed with the Recipient, who are or have been involved in this agreement. The Recipient carries the responsibility, that the persons who are involved in the agreement are informed and accept the processing and transfer of personal data., including name, contact details, and CVR-no in a global electronic system for processing of personal data. The electronic data processing system is accessible for a number of companies within the Pfizer group. The personal data can be transferred by Pfizer to other companies within the Pfizer group, to business partners as well as relevant governmental authorities, when this is necessary. Such recipients can be situated in countries outside the EC, e.g. the United States (so-called third-countries). For transfers from the EEA to countries not considered adequate by the European Commission, we have put in place adequate measures, such as by ensuring that the receiver is bound by EU Standard Contractual Clauses, to protect your personal data. By signing this Agreement the Recipient agrees that Pfizer may transfer such personal data to third countries in order to fulfil this Agreement and for the purpose of precise identification of Pfizer's business partners.

The Recipient is entitled to contact Pfizer, if the Recipient wishes to access the processed personal information about the Recipient. The Recipient is further entitled to have the relevant information changed or deleted. This applies for all persons mentioned in this section.

By signing this Agreement the Recipient confirms to have read and understood Pfizer's Representations and Warranties pursuant to Appendix A ("Representations and Warranties") and that the support is spent in accordance with the above mentioned terms and conditions.

We kindly ask you to return the signed agreement to Pfizer.

Signature of authorized signatory on behalf of Pfizer:

Dimitrios Maliokas

Date: 19/3/2026

Name: Dimitrios Maliokas

Title: EMEA MEET Operations Manager

Signature of authorized signatory on behalf of Danmarks Bløderforening:

Karen Binger Holm

Date: 20/3/2026

Name: Karen Binger Holm

Title: Sekretariatsleder

Appendix A - Representations and Warranties

- 1.1 The financial support from Pfizer will not cause your entity and, to your knowledge, any individuals affiliated with your entity or this support, to do anything that would result in Pfizer improperly obtaining or retaining business or gaining any improper business advantage;
- 1.2 Neither your entity nor, to your knowledge, any individuals affiliated with your entity or this support, will use any portion of the financial support from Pfizer to directly or indirectly offer or pay any money or anything of value in an effort to influence any Government Official or any other person in order for Pfizer to improperly obtain or retain business or to gain an improper business advantage, and, have not accepted, and will not accept in the future, such a payment;
- 1.3 If the support is an educational grant or otherwise to support an educational program, your entity agrees to disclose the fact that Pfizer is providing financial support for the educational program;
- 1.4 Pfizer may at any time publicly disclose that it has provided you with financial support, including the amount of such support; and
- 1.5 Pfizer will be entitled to revoke or suspend any financial support if Pfizer learns that your entity or any individuals affiliated with your entity or this support has used or intends to use any portion of the support to improperly seek to influence any Government Official or any other person in order to obtain or retain business or gain a business advantage.